Switch to:

Key Ratios

New Key Statistics Module, Z-Score and F-Score
Market Cap $M472Revenue $M156Net Margin (%)-39.9Z-Score0.8
Enterprise Value $M444EPS $-1.0Operating Margin %-24.9F-Score3
P/E(ttm))0Cash Flow Per Share $0.7Pre-tax Margin (%)-23.5Higher ROA y-yN
Price/Book1.710-y EBITDA Growth Rate %0Quick Ratio2.6Cash flow > EarningsY
Price/Sales2.85-y EBITDA Growth Rate %0Current Ratio2.7Lower Leverage y-yN
Price/Cash Flow16.2y-y EBITDA Growth Rate %-154.8ROA % (ttm)-12.5Higher Current Ratio y-yY
Dividend Yield %0Insider Buy (3m)0ROE % (ttm)-22.1Less Shares Outstanding y-yN
Payout Ratio %0Shares Outstanding M65.6ROI % (ttm)5.7Gross Margin Increase y-yY

Gurus Latest Trades with SPPI

Number of guru portfolios checked: 56. (List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)
TickerGuruDate Action
Impactdown Price Range
(Average)*
Current Price Change from Average Comment Current Shares
SPPIJohn Burbank 2012-12-31 Sold Out -0.13%$10.64 - $12.31
($11.39)
$ 7.2-37%Sold Out0
SPPIJoel Greenblatt 2012-12-31 Sold Out -0.02%$10.64 - $12.31
($11.39)
$ 7.2-37%Sold Out0
SPPIJoel Greenblatt 2012-12-31 Sold Out -0.02%$10.64 - $12.31
($11.39)
$ 7.2-37%Sold Out0
SPPIJohn Burbank 2012-09-30 Buy 0.13%$11.6 - $17.05
($13.85)
$ 7.2-48%New holding, 250000 sh.250,000
SPPIJoel Greenblatt 2012-09-30 Buy 0.02%$11.6 - $17.05
($13.85)
$ 7.2-48%New holding, 19901 sh.19,901
Premium Real Time Picks are included for Premium Members only!!
*The price and date might not be the actual time and price at which the transactions were made. In the case of institutional owners, the date is stated as the last day of their fiscal quarter. The prices are estimates if no accurate information available. Foreign holdings may not be included.

SPPI is held by these Gurus:

Premium Most recent portfolio changes are included for Premium Members only!


SPPI: Insider Buys/Sells

Click Here for All Insider Trades.
InsiderPosition Date Trades Shares Trade Price ($) Change (%) Details
MAIDA ANTHONY E IIIDirector 2013-03-05Sell5,000$11.5-37.39 view
MAIDA ANTHONY E IIIDirector 2013-02-05Sell5,000$12.25-41.22 view
MAIDA ANTHONY E IIIDirector 2013-01-02Sell5,000$11.42-36.95 view
SHROTRIYA RAJESH C MDChairman, CEO & President 2012-12-31Sell378,343$11.29-36.23 view
MAIDA ANTHONY E IIIDirector 2012-12-04Sell5,000$11.65-38.2 view
Keller Joseph KennethEVP & COO 2012-11-12Buy10,000$10.95-34.25 view
MAIDA ANTHONY E IIIDirector 2012-11-01Sell5,000$11.09-35.08 view
SHROTRIYA RAJESH C MDChairman, CEO & President 2012-10-09Sell11,350$12.5-42.4 view
MAIDA ANTHONY E IIIDirector 2012-10-02Sell5,000$11.8-38.98 view
Scott Brett LActing CFO 2012-10-01Sell6,000$12-40 view

Press Releases about SPPI :

    Quarterly/Annual Reports about SPPI:

    News about SPPI:

    Articles On GuruFocus.com
    http://seekingalpha. Aug 14 2012 
    Spectrum: Allos Acquisition Means Huge Upside Potential May 04 2012 
    5 Stocks Exceeding Expectations In 2012 Mar 31 2012 
    Was Gilead's Acquisition of Pharmasset a Dose of Bad Medicine? Mar 05 2012 
    Spectrum Pharmaceuticals Inc. Reports Operating Results (10-K) Mar 10 2011 
    Weekly CFO Buys Highlight: CNYD, PRWT, ANCB, SPPI, SPAX Jan 30 2011 
    Weekly CFO Buys Highlight: FUL, SPPI, GRF, BPAX Jan 24 2011 
    Weekly Top Insider Buys: NPBC, FUL, GAM, SHLM, SPPI Jan 23 2011 
    Spectrum Pharmaceuticals Inc. (SPPI) CFO Brett L Scott buys 4,000 Shares Jan 21 2011 
    Spectrum Pharmaceuticals Inc. Reports Operating Results (10-Q) Nov 04 2010 

    More From Other Websites
    Spectrum Pharma upgraded by R. F. Lafferty Jul 15 2014
    Spectrum Pharmaceuticals: Key Drug Fusilev May Face Generic Competition Soon Jul 09 2014
    Spectrum Pharmaceuticals Gains U.S. Approval of Beleodaq Jul 07 2014
    Spectrum receives accelerated FDA approval for Beleodaq Jul 07 2014
    Why Spectrum Pharmaceuticals (SPPI) Stock Is Higher This Morning Jul 07 2014
    FDA Grants Spectrum Pharmaceuticals Accelerated Approval of Beleodaq™ (belinostat) for Injection Jul 07 2014
    Spectrum Pharmaceuticals granted accelerated approval of lymphoma treatment Jul 07 2014
    FDA Grants Spectrum Pharmaceuticals Accelerated Approval of Beleodaq™ (belinostat) for Injection Jul 07 2014
    FDA approves lymphoma drug from Spectrum Pharma Jul 03 2014
    FDA approves lymphoma drug from Spectrum Pharma Jul 03 2014
    Spectrum Pharma Lymphoma Drug Approved Early Jul 03 2014
    Midday movers: Lorillard, PetSmart, Walgreen & More Jul 03 2014
    Spectrum Pharmaceuticals Shares Up 5% Following FDA Accelerated Approval For Beleodaq (SPPI) Jul 03 2014
    FDA approves Spectrum Pharma's blood cancer drug Jul 03 2014
    Spectrum confirms FDA approves Beleodaq, updates on PMRs for Beleodaq, Folotyn Jul 03 2014
    SPECTRUM PHARMACEUTICALS INC Files SEC form 8-K, Regulation FD Disclosure, Triggering Events That... Jul 03 2014
    SPECTRUM PHARMACEUTICALS INC Files SEC form 8-K, Submission of Matters to a Vote of Security Holders Jun 27 2014

    Add Notes, Comments or Ask Questions

    User Comments

    No comment yet
    Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
    GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
    Free 7-day Trial
    FEEDBACK
    Email Hide